All patients
Age < 65y (younger) Age > 75y (older) Asian type ECOG 0 ECOG 1 Gender, female Gender, male P16 positive (HPV) PD-L1 < 1% PD-L1 < 10% PDL1 (TC0 and IC0 : <1% of TC and IC) PDL1 (TC1/2/3 or IC1/2/3 : ≥1% of TC or IC) PDL1 < 25% PDL1 >25% smoker (Current) smoker (Former) smoker (never)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
metastatic-recurrent HNSCC (mHNSCC), durvalumab plus tremelimumab vs. chemotherapy, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results EAGLE (DT vs ICC), 2019 1.04 [0.85; 1.27]
1.04 [0.85 ; 1.27 ] EAGLE (DT vs ICC), 2019 1 0% 496 NA not evaluable progression or deaths (PFS)detailed results EAGLE (DT vs ICC), 2019 1.09 [0.90; 1.33]
1.09 [0.90 ; 1.33 ] EAGLE (DT vs ICC), 2019 1 0% 496 NA not evaluable DCRdetailed results EAGLE (DT vs ICC), 2019 1.12 [0.72; 1.75]
1.12 [0.72 ; 1.75 ] EAGLE (DT vs ICC), 2019 1 0% 496 NA not evaluable objective responses (ORR)detailed results EAGLE (DT vs ICC), 2019 1.07 [0.67; 1.70]
1.07 [0.67 ; 1.70 ] EAGLE (DT vs ICC), 2019 1 0% 496 NA not evaluable AE (any grade)detailed results EAGLE (DT vs ICC), 2019 0.80 [0.35; 1.79]
0.80 [0.35 ; 1.79 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable AE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 1.33 [0.93; 1.90]
1.33 [0.93 ; 1.90 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable AE leading to death (grade 5)detailed results EAGLE (DT vs ICC), 2019 1.32 [0.70; 2.46]
1.32 [0.70 ; 2.46 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable AE leading to treatment discontinuation (any grade)detailed results EAGLE (DT vs ICC), 2019 1.54 [0.89; 2.68]
1.54 [0.89 ; 2.68 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable SAE (any grade)detailed results EAGLE (DT vs ICC), 2019 1.39 [0.94; 2.06]
1.39 [0.94 ; 2.06 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable TRAE (any grade)detailed results EAGLE (DT vs ICC), 2019 0.34 [0.22; 0.52]
0.34 [0.22 ; 0.52 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.61 [0.39; 0.96]
0.61 [0.39 ; 0.96 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable TRAE leading to death (grade 5)detailed results EAGLE (DT vs ICC), 2019 3.93 [0.18; 87.52]
3.93 [0.18 ; 87.52 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable TRAE leading to discontinuation (any grade)detailed results EAGLE (DT vs ICC), 2019 0.97 [0.40; 2.39]
0.97 [0.40 ; 2.39 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Alopecia TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
0.98 [0.02 ; 49.37 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Anaemia TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.34 [0.11; 1.10]
0.34 [0.11 ; 1.10 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Asthenia TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 2.47 [0.47; 12.85]
2.47 [0.47 ; 12.85 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.65 [0.11; 3.91]
0.65 [0.11 ; 3.91 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Dermatitis acneiform TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
0.98 [0.02 ; 49.37 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.65 [0.11; 3.91]
0.65 [0.11 ; 3.91 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Fatigue TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 1.47 [0.24; 8.87]
1.47 [0.24 ; 8.87 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
0.98 [0.02 ; 49.37 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.49 [0.02; 14.58]
0.49 [0.02 ; 14.58 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Leucopenia TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.12 [0.01; 2.29]
0.12 [0.01 ; 2.29 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.49 [0.02; 14.58]
0.49 [0.02 ; 14.58 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Nausea TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
0.98 [0.02 ; 49.37 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Neutropenia TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.08 [0.01; 0.60]
0.08 [0.01 ; 0.60 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.24 [0.01; 5.40]
0.24 [0.01 ; 5.40 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Pruritus TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
0.98 [0.02 ; 49.37 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Rash TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
0.98 [0.02 ; 49.37 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 0.98 [0.02; 49.37]
0.98 [0.02 ; 49.37 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results EAGLE (DT vs ICC), 2019 1.96 [0.18; 21.75]
1.96 [0.18 ; 21.75 ] EAGLE (DT vs ICC), 2019 1 0% 486 NA not evaluable 0.0 10.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 04:06 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 276,103,277,102,109,278,101,192,114
- treatments: 634,861